Hospice enforcement has entered a structurally different phase. Oversight is no longer episodic or complaint‑driven; it is continuous, data‑driven, and predictive. Federal agencies increasingly identify risk through utilization analytics — length of stay, live discharges, diagnosis mix, and level‑of‑care patterns — before auditors ever review records. By the time a hospice receives an audit or payment action, the organization has often already been characterized as an outlier.
Recent enforcement illustrates this shift. In April 2026, federal authorities announced arrests in Operation Never Say Die, charging hospice operators with more than $50 million in alleged Medicare fraud. In the Topanga Hospice Care matter, investigators cited an 85% non‑death discharge rate — nearly five times the national average — as a key indicator that patients were not terminally ill. Data analytics surfaced the pattern; medical‑record review confirmed ineligibility. That same month, Centers for Medicare & Medicaid Services (CMS) imposed a nationwide six‑month moratorium on new hospice enrollments, signaling that regulators view hospice fraud risk as systemic rather than isolated.
From a leadership perspective, the most consequential insight is how eligibility is evaluated. Regulators assess hospice eligibility longitudinally, across the entire patient stay — not at isolated certification points. Admission decisions, recertifications, face‑to‑face encounters, interdisciplinary documentation, and discharge determinations are read as a single evidentiary record. Risk compounds when documentation supports eligibility early but weakens over time.
This approach is evident in recent False Claims Act (FCA) resolutions. In February 2025, Saad Healthcare Services paid $3 million to settle allegations that it billed Medicare for patients who were not terminally ill — an issue identified by tracing complete patient stays rather than individual claims. In July 2024, Gentiva Health Services (successor to Kindred at Home) agreed to pay $19.4 million to resolve multi‑state allegations involving billing for ineligible hospice patients, following a review of longitudinal documentation across multiple locations and years.
These cases underscore why documentation integrity functions as an enterprise risk control, not a clinical formality. In enforcement matters, documentation is the evidence. Where records are templated, repetitive, or internally inconsistent, regulators infer that eligibility determinations were perfunctory — regardless of the care delivered. In June 2025, Creative Hospice Care settled for $9.2 million following allegations that kickbacks to medical directors influenced referrals; the documentary record of those arrangements, rather than retrospective clinical judgment, drove the outcome.
Against this backdrop, leading hospice organizations are increasingly engaging independent, third‑party advisors to conduct full‑patient‑stay reviews. This is not an operational audit tactic; it is a governance strategy. Regulators review entire episodes of care. Independent, longitudinal reviews mirror that lens, identify eligibility drift early, and provide boards and executives with objective validation of risk — before analytics escalate exposure. In several recent settlements, voluntary disclosure and proactive internal investigation materially influenced outcomes.
For boards and executive teams, enforcement outcomes increasingly turn on how risk was governed, not simply whether issues existed. Effective oversight means ensuring compliance independence, monitoring benchmark data, investigating outliers promptly, and using independent validation to test internal assumptions. CMS reported 343 fraud referrals representing $3.4 billion in 2025 and revoked thousands of billing privileges — clear evidence that passive governance is no longer defensible.
Bottom Line
Data‑driven enforcement is permanent. Eligibility risk is cumulative. Documentation is the primary control lever. Hospice organizations that adopt proactive, advisory‑led governance — particularly independent, full‑stay eligibility review — are far better positioned to reduce FCA, Office of Inspector General (OIG), and CMS exposure and to demonstrate credible leadership in an increasingly scrutinized sector.
© Copyright 2026. The views expressed herein are those of the author(s) and not necessarily the views of Ankura Consulting Group, LLC, its management, its subsidiaries, its affiliates, or its other professionals. Ankura is not a law firm and cannot provide legal advice.
